Human monoclonal antibodies (Mabs) will become essential for the prophylaxis and
treatment of human disease. There are three conceptual approaches to producing human
MAbs including (1) transformation of antigen-specific B lymphocytes by Epstein-Barr virus
(EBV), as first carried out by Steinitz et al., 1 (2) hybridization of 6-thioguanine-resistant (6-
TG r) human plasmacytomas or lymphoblastoid fusion partners to immune human
lymphocytes, as first demonstrated in the mouse by K6hler and Milstein 2 and adapted to the …